Updates in Bone Management - BMD at Menopause to consider MHT for long term Osteoporosis prevention.

You are invited to join us at Ponti Health for the most recent updates on Bone Management with a particular focus on BMD at menopause, MHT and Osteoporosis.

Learn about Australia's first medically led REMS (Radiofrequency Echographic Multi Spectrometry) scanner, providing an advanced alternative for the diagnosis, screening, and monitoring of osteoporosis.

The Panel:

- Dr Amanda Beech is an Obstetric Medicine Physician and Endocrinologist at the Royal Hospital for Women and Prince of Wales Private Hospitals. She holds a conjoint lecturer position at The University of NSW. She has extensive experience in menopause, osteoporosis, reproductive endocrinology and obstetric medicine.

- Dr Anna Connellan is a General Practitioner (Chief Medical Officer) at Ponti Health with a special interest in women’s health. She has considerable experience in women's health across all ages, is the chair of the Royal Hospital for Women’s antenatal shared care committee and is a member of the Australasian Menopause Society.

-Dr Dennis Chan is a specialist endocrinologist and general physician Dr Chan brings unique expertise in osteoporosis, not only as a specialist but also as an experienced clinical densitometrist, having interpreted and reported numerous DXA scans. Notably, he is the first medical practitioner in Australia to offer REMS (Radiofrequency Echographic Multi Spectrometry), providing an advanced alternative for the diagnosis, screening, and monitoring of osteoporosis.

⏲️

- 6.00pm: Registrations, canapés and drinks

- 6.30pm: Panel discussion

- 8.00pm: Event concludes

If you have any questions or require parking, please email us at enquiries@pontihealth.com

We are supporting WHRIA with the recruitment of participants of MiGel (Ovestin & Amitriptyline) trial and we’d welcome your input. Dr Karen Chan (Gynaecologist and Pain Specialist) and the team at WHRIA are conducting a clinical trial to investigate the potential effect of a topical medication for the treatment of vulval/vaginal pain with sexual activity.

Research representatives from WHRIA will be present on the evening.